• Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 iwCLL criteria1.
• Previously received treatment for CLL/SLL with a cBTKi. Patients should have disease relapsed after or refractory to at least 1 line of therapy including a cBTKi. Patients who discontinue cBTKi due solely to toxicity are not eligible  NOTE: A line of therapy is considered 2 or more consecutive cycles of a systemic anticancer regimen
• Patients with SLL must have measurable disease by computed tomography/magnetic resonance imaging, defined as ≥ 1 lymph node > 1.5 cm in longest diameter and measurable in 2 perpendicular diameters

1. Known prolymphocytic leukemia or history of, or currently suspected, Richter’s

transformation.

2. Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the

last 3 months.

3. Prior allogeneic stem cell transplant ≤ 6 months before the first dose of the study drug

(Note: patients who have previously received allogeneic stem cell transplant must have

no signs or symptoms of graft versus host disease and must not be receiving

immunosuppressive therapy.)

4. Patients who have a history of severe allergic reactions or hypersensitivity to the active

ingredient and excipients of study drug.

5. Patients who are unable to comply with the requirements of the protocol.

6. Current or history of central nervous system involvement including the brain, spinal cord,

leptomeninges, and cerebrospinal fluid (as documented by imaging, cytology, or biopsy)

by CLL/SLL.